Intrinsiqq
Guardant Health Inc. logo

Guardant Health Inc. Financials

GH

⊜ Compare

All currency values in $ millions unless otherwise noted

Scroll

Showing 6 of 10 available years
Income Statement
TTM
DEC 2025
DEC 2024
DEC 2023
DEC 2022
DEC 2021
Revenues
Revenue$1,183$982$739$564$450$374
Cost of Revenue$414$349$290$227$456$315
Gross Profit$769$633$449$337-$7$59
Operating Expenses
Selling & Marketing$630$495$365$295$300$192
General & Administrative$234$211$180$156$164$207
Research & Development$376$364$348$367$374$263
Other Operating Expenses–$0$0$83$0$0
Total Operating Expenses$1,653$1,419$1,183$1,129$994$785
Operating Income-$470-$437-$444-$565-$544-$411
Non-Operating
Net Interest Expense$34$30$51$33$3$1
Other Non-Operating Income (Expense)-$18-$10-$43$53-$113$25
EBT (Earnings Before Tax)-$454-$418-$435-$479-$653-$384
Income Tax Expense-$1-$1$1$1$1$0
Net Income
Net Income-$453-$416-$436-$479-$655-$385
Per Share Data
Revenue Per Share$8.90$7.83$6.02$5.04$4.40$3.69
EPS (Basic)-$3.50-$3.32-$3.56-$4.28-$6.41-$4.00
EPS (Diluted)-$3.50-$3.32-$3.56-$4.28-$6.41-$4.00
Weighted Avg Shares (Basic)132.9M125.4M122.7M112.0M102.2M101.3M
Weighted Avg Shares (Diluted)132.9M125.4M122.7M112.0M102.2M101.3M
Shares Outstanding132.9M125.4M122.7M112.0M102.2M101.3M

Guardant Health (GH) financials: revenue, profit and margins

Guardant Health (GH) generated about $1.2 billion in revenue and -$453 million in net income (a -38.3% net margin) over the trailing twelve months, growing at roughly 27.9% a year. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

What is Guardant Health's (GH) revenue?+

Guardant Health generated about $1.2 billion in revenue over the trailing twelve months. Revenue has grown at roughly 27.9% a year over the past five years. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.

Is Guardant Health profitable?+

Guardant Health reported about -$453 million in net loss over the trailing twelve months, a net margin of roughly -38.3%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

What are Guardant Health's profit margins?+

Guardant Health runs a gross margin of about 65.0%, an operating margin of about -39.7%, a net margin of about -38.3%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.

How fast is Guardant Health growing?+

Guardant Health's revenue has compounded at roughly 27.9% a year over the past five years. Growth only creates value when it is profitable and cash-generative, so read this rate alongside GH's margins and free cash flow. This is analysis from SEC filings, not investment advice.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 24 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 31 Jul 2026. How this is calculated.

Fiscal year ends Dec.

Peers

Services-Medical Laboratories · Pick stocks to compare with GH

CompareIntrinsic value
CAICaris Life Sciences, Inc.
$32.31-1.66%71
VCYTVeracyte Inc.
$52.52+4.43%68
CDNACareDx Inc.
$85.86-2.95%57
BLLNBillionToOne, Inc.
$113.89+3.11%63
CSTLCastle Biosciences, Inc.
$35.75+1.74%40
FLGTFulgent Genetics Inc.
$19.68+1.60%20
RDNTRadNet Inc.
$80.26+9.67%39
GRALGrail, Inc.
$143.79+3.12%40

Held by ETFs

GH is in 148 US ETFs. The largest of them, with GH's weight in each:

Spot a number that looks wrong? Check it in GH's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing GH

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.